Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer By Ogkologos - July 15, 2025 492 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POD1UM-303/InterAACT-2 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with... December 6, 2024 Cancer in My Community: The 3 Ways People Access Cancer Care... February 2, 2023 The HPV Vaccine: Increasing the Use of an Important Cancer Prevention... December 20, 2018 Happy New Year From Our Team January 4, 2021 Load more HOT NEWS Exceptional Response to Single-Agent Anti-PD1 Therapy Observed in Patients with Advanced... Should People With Cancer Be Tested for Hepatitis B? Encorafenib, Cetuximab Combination Approved for Metastatic Colorectal Cancer Cancer Does Not Affect All People Equally: An Expert Q&A on...
